EP1441721A2 - Utilisation d'antagonistes du recepteur de l'endotheline dans le traitement de maladies tumorales - Google Patents
Utilisation d'antagonistes du recepteur de l'endotheline dans le traitement de maladies tumoralesInfo
- Publication number
- EP1441721A2 EP1441721A2 EP02802624A EP02802624A EP1441721A2 EP 1441721 A2 EP1441721 A2 EP 1441721A2 EP 02802624 A EP02802624 A EP 02802624A EP 02802624 A EP02802624 A EP 02802624A EP 1441721 A2 EP1441721 A2 EP 1441721A2
- Authority
- EP
- European Patent Office
- Prior art keywords
- benzothiadiazol
- methoxyphenyl
- furan
- hydroxy
- unsubstituted
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/472—Non-condensed isoquinolines, e.g. papaverine
- A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/4035—Isoindoles, e.g. phthalimide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/433—Thidiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/443—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with oxygen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4436—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Definitions
- the invention relates to the use of endothelin receptor agonists selected from the group
- R 1 , R 2 , R 3 are missing independently of one another, H, Hai, A, CF 3 , N0 2 , NR 4 R 5 , CN, COOR 4 , NHCOR 4 ,
- R 4 , R 5 each independently of one another H or A, together also -CH 2 - (CH 2 ) n -CH 2 -,
- X is a saturated, fully or partially unsaturated 3 to
- Atoms can be replaced by N and / or 1 to 2 C atoms by 1-2 0 and / or 1-2 S atoms, but at most up to 3 C atoms are replaced and additionally one or two - or triple
- Groups and 1-7 H atoms can be replaced by F,
- R J Ar, R 4 , R 4 ' each independently of one another are H, alkyl having 1 to 6 carbon atoms or benzyl,
- Ar is phenyl or naphthyl which is unsubstituted or mono-, di- or trisubstituted by R 5 , R 6 or R 7 or an unsubstituted or mono- or disubstituted by R 5 or R 6 in the phenyl moiety
- R 5 , R 6 , R 7 each independently of one another R 4 , OR 4 , shark, CF 3 , OCF 3) OCHF 2 , OCH 2 F, N0 2 , NR 4 R 4 ', NHCOR 4 , CN, NHS0 2 R 4 , COOR 4 , COR 4 , CONHS0 2 R 8 , 0 (CH 2 ) n R 2 , OPh, 0 (CH 2 ) n OR 4 or S (0) m R 4 ,
- R 8 unsubstituted or single, double or triple by A
- R ⁇ , R 6 ' each independently of one another H, alkyl with 1 to 6
- R 10 or R 11 substituted phenyl or unsubstituted naphthyl or one unsubstituted or mono- or disubstituted in the phenyl part by R 9 or R 10
- R, R ⁇ 10, ⁇ R11 each independently of one another R, O vRr ⁇ 6, Hai, CF 3) OCF 3 , OCHF 2 , OCH 2 F, N0 2 , NR 6 R 6 ', NHCOR 6 , CN, NHS0 2 R 6 , COOR 6 , COR 6 , CONHS0 2 Ar, 0 (CH 2 ) n R 2 0 (CH 2 ) n OR 6 or S (0) m R 6 ,
- X is 0 or S, m is 0, 1 or 2, n is 1 or 2, and their salts;
- R ö Ar or OAr Ar unsubstituted or single, double or triple by R 9 ,
- R 10 or R 11 substituted phenyl or unsubstituted naphthyl or one unsubstituted or mono- or disubstituted in the phenyl part by R 9 or R 10
- R 9 , R 10 , R 11 each independently of one another R, OR, Hai, CF 3 ,
- R d CN, COOH, COOA, CONHS0 2 R or 1 H-tetrazol-5-yl, R 4 , R 4 ' each independently of one another H, A or unsubstituted or simply substituted by alkoxy phenyl or benzyl
- R 6 unsubstituted or one, two or three times by A
- a alkyl with 1 -6 C atoms, in which one or two CH 2 groups are represented by O or S atoms or by -CR 4 CR 4 '-
- Groups and also 1-7 H atoms can be replaced by F or benzyl, Ar unsubstituted or one, two or three times by A,
- OR 4 NH 2 , NHA, NA 2 , N0 2 , CN, Hai, NHCOR 4 , NHS0 2 R 4 , COOR 4 , COR 4 , CONHS0 2 R 6 , 0 (CH 2 ) n R 3 , OPh, 0 ( CH 2 ) n OR 4 or S (0) m R 4 substituted phenyl or naphthyl,
- X is 0 or S, m is 0, 1 or 2, n is 1 or 2, and their salts;
- R 1 H shark, OH, OA, A, alkylene-OA, N0 2 , NH 2 , NHAcyl, S0 2 NH 2 , S0 3 -A, S0 2 NHA, CN or formyl,
- R 3 , R 5 , R 6 each independently of one another H, Hai, OH, OA,
- R 3 and R 6 together also -0-CH 2 -0-, -0-CH 2 -CH 2 -0-, -0-CH 2 -CH 2 -, -O-CF ⁇ -O- or -0- CF 2 -CF 2 -0-,
- R is phenyl unsubstituted or mono- or polysubstituted by R 3 and / or R 6 , alkyl having 1-6 C atoms, Hal is fluorine, chlorine, bromine or iodine, n is 1 or 2, and their salts;
- R 1 H shark, OH, OA, A, alkylene-OA, N0 2 , NH 2 , NHAcyl,
- R 2 , R 3 , R 4 each independently an unsubstituted or one or more times by shark, OH, OA,
- R 2 additionally denotes A or cycloalkyl
- R a is an unsubstituted or singly or multiply by shark, OH, OA, A, SA, N0 2 , NH 2 , NHA, NA 2 , NHAcyl, NHS0 2 A, NAS0 2 A, NH (CO) NH 2 , NH ( CO) NHA, formyl, NHCOOA, NAAcyl, NHCOO-alkylene-OA, NH (CO) NA 2 , N-piperidinyl-CO-NH, N-pyrrolidinyl-CONH, 0 (CH 2 ) n COOA, 0 (CH 2 ) n COOH, 0 (CH 2 ) n OH, 0 (CH 2 ) n OA, CH 2 OH, CH 2 OA, COOH, COOA, CH 2 COOH or CH 2 COOA substituted phenyl group, alkyl with 1 -6 C atoms, in which one or two CH 2 groups can be replaced by O or S atoms or by -
- R 6 and R 6 ' are each independently of one another H, F or A,
- 5 m denotes 1 or 2, or a tautomeric ring-closed form, and also the (E) isomers and the salts of all isomers;
- R, R, R are missing independently of one another, H, Hai, A, CF 3) N0 2 , NR 4 R 5 , CN, COOR 4 or NHCOR 4 ,
- R, R each independently of one another H or A, or together also -CH 2 - (CH 2 ) n -CH 2 -, 30 R 6 is an unsubstituted or one, two or three times by R 7 , R 8 and / or R 9 substituted phenyl radical, benzothiadiazol-5-yl or benzoxadiazol-5-yl radical,
- R 7 , R 8 , R 9 each independently of one another A, OA, CN, COOH,
- R 1 Ar, R 2 H unsubstituted or single, double or triple
- R 3 , R 3 ' each independently of one another H, alkyl with 1-6 C-
- R 7 or R 8 substituted phenyl or an unsubstituted or in the phenyl part simply substituted by R 6
- R 6 , R 6 ' each independently of one another R 3 , OR 3 or shark, R 7 R 3 , OR 3 , shark, N0 2 , NH 2 , NHR 3 , NR 3 R 3 ', NHCOR 3 ,
- Ph is phenyl, m is 0 or 1, n is 1 or 2, and their salts;
- R unsubstituted or one, two or three times by R 3 ,
- R 4 or R 5 substituted phenyl or unsubstituted or simply substituted by R 2 2,1,3-benzothidiazolyl,
- R 1 A in which 1-7 H atoms can be replaced by F
- R 2 A, F, Cl, Br or -OA, R 3 , R 4 , R 5 each independently of one another A, -OA, -SA,
- R 3 and R 4 together also mean -0-CH 2 -0- and A alkyl having 1 -7 C atoms, and their salts;
- R 1 H shark, OH, OA, A, alkylene-OA, N0 2) NH 2 , NHAcyl, S0 2 NH 2 , S0 3 -A, S0 2 NHA, CN or formyl,
- R 2, R 3, R 4 are each independently an unsubstituted or mono- or polysubstituted by R 7 phenyl group, wherein R 2 is additionally A or cycloalkyl, a
- R 3 or R 4 is an unsubstituted or R 8 radical which is mono- or polysubstituted by R 7 ,
- Groups and / or 1-7 H atoms can be replaced by F,
- R 'Hai OH, OA, O-alkylene-R 5 , A, SA, S-OA, S0 2 A, S-
- R 1 H shark, OH, OA, A, N0 2 , NH 2 , NHA, NAA ', NHCOR 4 ,
- R 2 , R 2 ' are each independently A, (CH 2 ) n Ar, (CH 2 ) n Het, CH 2 COAr, CH 2 COHet or OAr,
- R 2 ' additionally also H
- R 3 COOR 4 , CN, 1 H-tetrazol-5-yl or CONHS0 2 R 5 ,
- RR 44 ,, RR 44 ' each independently of one another H or A,
- R 6 is phenyl or naphthyl which is unsubstituted or mono-, di- or trisubstituted by A, NH 2 , NHA, NAA ', N0 2 , CN or shark,
- R 7 , R 7 each independently of one another H or alkyl with 1-6 C-
- Atoms in which one or two CH 2 groups can be replaced by O or S atoms or by -CR 7 CR 7 groups and / or 1-7 H atoms by F, or benzyl,
- NHCOR 6 NHS0 2 R 4 , NHS0 2 R 6 , COOR 4 , OPh, CONH 2) CONHA, CONAA ', COR 4 , CONHS0 2 R 4 , CONHS0 2 R 6 , 0 (CH 2 ) n COOR 4 , 0 ( CH 2 ) n OR 4 , S0 3 H, S0 2 NR 4 R 4 ', S (0) m R 6 or S (0) m R 4 substituted phenyl or
- Shark is fluorine, chlorine, bromine or iodine, m is 0, 1 or 2 and n is 1 or 2, where, if R 2 is CH 2 COAr and R 2 ' H, R 3 is not COOA, and the salts thereof;
- R 1 is an unsubstituted or simply substituted in the phenyl part by R 7
- R 2 A Ar- (CH 2 ) m , cycloalkyl- (CH 2 ) m , Het- (CH 2 ) m or R - (CH 2 ) m , R 3 , R 3 'each independently of one another OR 4 , NHS0 2 R 5 , NH 2 ,
- NHA or NAA ', R 3 and R 3 ' together also -O-, thereby forming a cyclic anhydride, R 4 , R 4 'each independently of one another H or A, R 5 A or Ar,
- R 6 unsubstituted or one, two or three times by A
- R 7 A COOR 4 , CN, 1 H-tetrazol-5-yl, CONHS0 2 R 5 , shark, OR 4 ,
- A, A 'each independently of one another alkyl having 1 -6 C atoms, in which one or two CH 2 groups by O or S atoms or by -CR 8 CR 8' groups and / or 1-7 H- Atoms can be replaced by F, or benzyl, Ar unsubstituted or one, two or three times by A,
- X, Y are each independently O or S,
- R 1 H shark, OH, OA, A, alkylene-OA, N0 2 , NH 2 , NHAcyl,
- NH (CO) NHR 5 NHCOOA, NAAcyl, NHCOOCH 2 R 5 , NHS0 2 CH 2 R 5 , NHCOO-alkylene-OA, NH (CO) NA 2 , 1-piperidinyl-CO-NH, 1-pyrrolidinyl-CONH, 0 (CH 2 ) n COOA, 0 (CH 2 ) n COOH, 0 (CH 2 ) n OH,
- R 2 additionally denotes A or cycloalkyl
- R is an unsubstituted or one or more sharks
- Cycloalkyl in which 1-2 carbon atoms can be replaced by N, O and / or S, R 9 is phenyl which is unsubstituted or mono- or disubstituted by shark,
- Naphthyl, A-0-C ( 0) - or shark, shark fluorine, chlorine, bromine or iodine, n represents 0, 1 or 2 and m 1 or 2, and their salts;
- X NR 3 O or S, R 2,1, 3-benzothiadiazol-4- or 5-yl or 2,1-benzoisothiazol-5- or 6-yl, unsubstituted or mono- or disubstituted by R 2 and / or R 2 ', or unsubstituted or mono- , phenyl which is substituted twice or three times by R and / or R 2 ' , R 1 H or A,
- R 2 , R 2 ' each independently of one another H, A, OH, OA, shark, OCF 3 , OCHF 2 , -O-CO-A, -O-alkylene-COOR 1 ,
- R 4 each independently of one another H, A, OH, OA, shark,
- R 2 , R 3 , R 5 , R 6 each independently of one another H, Hai, A, OA or R 4 ,
- R s and R 5 ' each independently of one another H, F or A,
- Hai is fluorine, chlorine, bromine or iodine, n is 0, 1 or 2, or a tautomeric ring-closed form, and also the (E) isomers and the salts of all isomers, for the manufacture of a medicament for inhibiting the growth of neoplastic cells.
- Tumor treatment is e.g. in WO 99/06397, WO 98/57933 or WO
- the object of the invention was to provide new uses of medicaments in the form of pharmaceutical preparations which have better properties than known medicaments which can be used for the same purposes.
- the compounds show, among other things, a high affinity for the endothelin subreceptors ET A and ET B.
- the compounds of formula I can be used as active pharmaceutical ingredients in human and veterinary medicine. They can also be used as intermediates for the production of further active pharmaceutical ingredients.
- Neoplastic cells are understood to mean cancer cells. Endothelin has a role in the following types of cancer:
- patients with metastatic prostate cancer have higher ET-1 plasma levels
- ET 1 stimulates proliferation of various prostate cancer cell lines
- ET-1 stimulates osteoblasts (Nelson JB et al. Nature Medicine 1/9 944-949,
- ET-1 stimulates bone formation in an osteoblat tumor model
- ET-1 influences the metastasis formation of prostate cancer.
- Atrasentan Abbott, Endothelin A receptor antagonist
- Ovarian cancer Ovarian cancer:
- ET-1 stimulates proliferation of primary ovarian cancer cells
- BQ123 selective endothelin A receptor antagonist
- ET-1 protects ovarian cancer cells from apoptosis. This can be done through BQ123
- ET-1 stimulates the proliferation of colon cancer cell lines. This can be done by
- BQ123 and BQ610 selective endothelin A receptor antagonists
- ET-1 is overexpressed in tumors from colon cancer patients.
- BQ123 selective endothelin A receptor antagonist
- BQ123 inhibits metastasis formation in a rat metastasis model (Asham E et al. British Journal of Cancer 81/11, 1759-1763, 2001). Cervical carcinoma:
- HPV positive cervical carcinomas express ET-1 and overexpress endothelin A receptor.
- ET-1 stimulates tumor cell proliferation. This can be inhibited by BQ123. (Venuti A et al., FASEB 14/14, 2279-2283, 2000)
- the endothelin B receptor plays a role in melanoma: Melanoma cells overexpress endothelin B receptor.
- Ro 61-612 / 001 an endothelin A and endothelin B receptor antagonist inhibits the proliferation of pancreatic tumor cells (ASPC-1) in vivo
- the invention preferably relates to the use of endothelin receptor antagonists selected from the group
- the invention relates in particular to the use of endothelin receptor antagonists selected from the group
- endothelin receptor antagonists which have a high affinity for the ET A receptor is particularly preferred.
- the invention furthermore relates to the use of the compounds of the formulas I and of the preferred compounds described above and their physiologically acceptable salts and / or solvates for the production of a medicament for the treatment and / or prophylaxis of cancer.
- the invention further relates to the use of the compounds mentioned, the cancers being selected from the group prostate cancer, ovarian cancer, colon cancer, cervical cancer, melanoma, pancreatic cancer.
- the invention furthermore relates to the use of the compounds of the formula I and the preferred compounds described above, and their physiologically acceptable salts and / or solvates for
- the invention furthermore relates to the use of the compounds of the formula I and the preferred compounds described above, and their physiologically acceptable salts and / or solvates for
- Precancerogenic damage means e.g. benign
- Precancerogenic damage includes in particular those in US
- Cell growth such as benign prostatic hyperplasia, new rod-general diseases, e.g. Parkinson,
- Autoimmune diseases including multiple sclerosis and rheumatoid arthritis or infectious diseases such as AIDS.
- the compounds of the formula I modulate apoptosis and are used in the treatment or prophylaxis of cancer.
- the invention thus relates to the use of those described
- the invention furthermore relates to the use of the compounds of the formulas I and the preferred compounds described above and / or their physiologically acceptable salts for the production of pharmaceutical preparations, in particular in a non-chemical way. They can be brought into a suitable dosage form together with at least one solid, liquid and / or semi-liquid carrier or auxiliary and, if appropriate, in combination with one or more further active ingredients.
- Suitable carriers are organic or inorganic substances that are suitable for enteral (e.g. oral), parenteral or topical application and with the new ones
- Benzyl alcohols alkylene glycols, polyethylene glycols, glycerol triacetate,
- Gelatin carbohydrates such as lactose or starch, magnesium stearate, talc,
- Vaseline Tablets, pills, dragees, capsules, powders, granules, syrups, juices or drops are used for oral use, suppositories for rectal use, solutions, preferably oily or aqueous solutions, furthermore suspensions, emulsions or implants for topical use for parenteral use Ointments, creams or powder.
- the new compounds can also be lyophilized and the lyophilizates obtained used, for example, for the production of injectables.
- the specified preparations can be sterilized and / or auxiliary substances such as lubricants, preservatives, stabilizers and / or wetting agents, emulsifiers, salts for influencing the osmotic pressure, buffer substances, coloring, taste and / or contain several other active ingredients, for example one or more vitamins. They can also be administered as nasal sprays.
- auxiliary substances such as lubricants, preservatives, stabilizers and / or wetting agents, emulsifiers, salts for influencing the osmotic pressure, buffer substances, coloring, taste and / or contain several other active ingredients, for example one or more vitamins. They can also be administered as nasal sprays.
- the substances are generally preferably used in doses between about 1 and 500 mg, in particular between 5 and 100 mg
- Dosage unit administered is preferably between about 0.02 and 10 mg / kg body weight.
- the specific dose for each patient depends on a wide variety of factors, for example on the effectiveness of the specific ones used
- connection age, body weight, general state of health, gender, diet, time and route of administration, excretion rate, drug combination and severity of the respective disease to which the therapy applies. Oral application is preferred.
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Heterocyclic Compounds That Contain Two Or More Ring Oxygen Atoms (AREA)
- Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE10155076 | 2001-11-09 | ||
DE10155076A DE10155076A1 (de) | 2001-11-09 | 2001-11-09 | Verwendung von Endothelin-Rezeptor-Antagonisten zur Behandlung von Tumorerkrankungen |
PCT/EP2002/011350 WO2003039539A2 (fr) | 2001-11-09 | 2002-10-10 | Utilisation d'antagonistes du recepteur de l'endotheline dans le traitement de maladies tumorales |
Publications (1)
Publication Number | Publication Date |
---|---|
EP1441721A2 true EP1441721A2 (fr) | 2004-08-04 |
Family
ID=7705184
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP02802624A Withdrawn EP1441721A2 (fr) | 2001-11-09 | 2002-10-10 | Utilisation d'antagonistes du recepteur de l'endotheline dans le traitement de maladies tumorales |
Country Status (15)
Country | Link |
---|---|
US (1) | US20050014769A1 (fr) |
EP (1) | EP1441721A2 (fr) |
JP (1) | JP2005510511A (fr) |
KR (1) | KR20050035181A (fr) |
CN (1) | CN1585636A (fr) |
AR (1) | AR037343A1 (fr) |
BR (1) | BR0213684A (fr) |
CA (1) | CA2465744A1 (fr) |
DE (1) | DE10155076A1 (fr) |
HU (1) | HUP0402281A2 (fr) |
MX (1) | MXPA04004306A (fr) |
PL (1) | PL369822A1 (fr) |
RU (1) | RU2004117596A (fr) |
WO (1) | WO2003039539A2 (fr) |
ZA (1) | ZA200404544B (fr) |
Families Citing this family (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB0219660D0 (en) | 2002-08-23 | 2002-10-02 | Astrazeneca Ab | Therapeutic use |
GB0223367D0 (en) * | 2002-10-09 | 2002-11-13 | Astrazeneca Ab | Therapeutic treatment |
GB0223854D0 (en) * | 2002-10-12 | 2002-11-20 | Astrazeneca Ab | Therapeutic treatment |
GB0320806D0 (en) * | 2003-09-05 | 2003-10-08 | Astrazeneca Ab | Therapeutic treatment |
GB0403744D0 (en) | 2004-02-20 | 2004-03-24 | Astrazeneca Ab | Chemical process |
WO2005095972A2 (fr) * | 2004-03-19 | 2005-10-13 | Bayer Healthcare Ag | Composes destines au diagnostic et au traitement de maladies associees au recepteur couple aux proteines g etb (etb) |
ITMI20040874A1 (it) * | 2004-04-30 | 2004-07-30 | Ist Naz Stud Cura Dei Tumori | Derivati indolici ed azaindolici con azione antitumorale |
GB0425854D0 (en) * | 2004-11-25 | 2004-12-29 | Astrazeneca Ab | Therapeutic treatment |
GB0514743D0 (en) * | 2005-07-19 | 2005-08-24 | Astrazeneca Ab | Salt |
US7939545B2 (en) * | 2006-05-16 | 2011-05-10 | Boehringer Ingelheim International Gmbh | Inhibitors of human immunodeficiency virus replication |
KR100989141B1 (ko) * | 2007-05-14 | 2010-10-20 | 경희대학교 산학협력단 | 시클로옥시게나제-2 저해제 |
WO2008140251A2 (fr) * | 2007-05-14 | 2008-11-20 | University-Industry Cooperation Group Of Kyung Hee University | Inhibiteurs de la cyclooxygénase-2 |
EP2220076B1 (fr) | 2007-11-15 | 2012-01-18 | Boehringer Ingelheim International GmbH | Inhibiteurs de la réplication du virus de l'immunodéficience humaine |
CN101918365B (zh) | 2007-11-16 | 2013-10-09 | 吉联亚科学股份有限公司 | 人类免疫缺陷病毒复制的抑制剂 |
CA2803292C (fr) | 2010-06-30 | 2016-06-14 | Ironwood Pharmaceuticals, Inc. | Stimulateurs de sgc |
EP2637659B1 (fr) | 2010-11-09 | 2016-05-18 | Ironwood Pharmaceuticals, Inc. | Stimulateurs de sgc |
CA2861804C (fr) | 2011-12-27 | 2021-10-26 | Ironwood Pharmaceuticals, Inc. | Pyrazoles 2-benzyle, 3-(pyrimidin-2-yle)-substitues utiles comme stimulateurs de scg |
US10183949B2 (en) | 2014-08-29 | 2019-01-22 | The University Of Tokyo | Pyrimidinone derivative having autotaxin-inhibitory activity |
Family Cites Families (20)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6063911A (en) * | 1993-12-01 | 2000-05-16 | Marine Polymer Technologies, Inc. | Methods and compositions for treatment of cell proliferative disorders |
DE19509950A1 (de) * | 1995-03-18 | 1996-09-19 | Merck Patent Gmbh | Endothelin-Rezeptor-Antagonisten |
DE19527568A1 (de) * | 1995-07-28 | 1997-01-30 | Merck Patent Gmbh | Endothelin-Rezeptor-Antagonisten |
WO1997004772A1 (fr) * | 1995-08-02 | 1997-02-13 | Smithkline Beecham Corporation | Antagonistes des recepteurs a l'endotheline |
DE19528418A1 (de) * | 1995-08-02 | 1997-02-06 | Merck Patent Gmbh | Endothelin-Rezeptor-Antagonisten |
DE19530032A1 (de) * | 1995-08-16 | 1997-02-20 | Merck Patent Gmbh | Endothelin-Rezeptor-Antagonisten |
DE19537548A1 (de) * | 1995-10-09 | 1997-04-10 | Merck Patent Gmbh | Endothelin-Rezeptor-Antagonisten |
JPH09124620A (ja) * | 1995-10-11 | 1997-05-13 | Bristol Myers Squibb Co | 置換ビフェニルスルホンアミドエンドセリン拮抗剤 |
DE19543639A1 (de) * | 1995-11-23 | 1997-05-28 | Merck Patent Gmbh | Endothelin-Rezeptor-Antagonisten |
DE19606980A1 (de) * | 1996-02-24 | 1997-08-28 | Merck Patent Gmbh | Endothelin-Rezeptor-Antagonisten |
DE19607096A1 (de) * | 1996-02-24 | 1997-08-28 | Merck Patent Gmbh | Endothelin-Rezeptor-Antagonisten |
DE19609597A1 (de) * | 1996-03-12 | 1997-09-18 | Merck Patent Gmbh | Endothelin-Rezeptor-Antagonisten |
DE19612101A1 (de) * | 1996-03-27 | 1997-10-02 | Merck Patent Gmbh | Endothelin-Rezeptor-Antagonisten |
DE19653037A1 (de) * | 1996-12-19 | 1998-06-25 | Merck Patent Gmbh | Endothelin-Rezeptor-Antagonisten |
DE19653024A1 (de) * | 1996-12-19 | 1998-06-25 | Merck Patent Gmbh | Endothelin-Rezeptor-Antagonisten |
DE19710831A1 (de) * | 1997-03-15 | 1998-09-17 | Merck Patent Gmbh | Endothelin-Rezeptor-Antagonisten |
DE19711428A1 (de) * | 1997-03-19 | 1998-09-24 | Merck Patent Gmbh | Endothelin-Rezeptor-Antagonisten |
DE19711785A1 (de) * | 1997-03-21 | 1998-09-24 | Merck Patent Gmbh | Endothelin-Rezeptor-Antagonisten |
DE19712141A1 (de) * | 1997-03-22 | 1998-09-24 | Merck Patent Gmbh | Endothelin-Rezeptor-Antagonisten |
DE19731571A1 (de) * | 1997-07-23 | 1999-01-28 | Merck Patent Gmbh | Endothelin-Rezeptor-Antagonisten |
-
2001
- 2001-11-09 DE DE10155076A patent/DE10155076A1/de not_active Withdrawn
-
2002
- 2002-10-10 JP JP2003541830A patent/JP2005510511A/ja active Pending
- 2002-10-10 CA CA002465744A patent/CA2465744A1/fr not_active Abandoned
- 2002-10-10 MX MXPA04004306A patent/MXPA04004306A/es not_active Application Discontinuation
- 2002-10-10 RU RU2004117596/15A patent/RU2004117596A/ru not_active Application Discontinuation
- 2002-10-10 BR BR0213684-8A patent/BR0213684A/pt not_active Application Discontinuation
- 2002-10-10 CN CNA028222520A patent/CN1585636A/zh active Pending
- 2002-10-10 HU HU0402281A patent/HUP0402281A2/hu unknown
- 2002-10-10 WO PCT/EP2002/011350 patent/WO2003039539A2/fr not_active Application Discontinuation
- 2002-10-10 KR KR1020047007032A patent/KR20050035181A/ko not_active Application Discontinuation
- 2002-10-10 US US10/495,108 patent/US20050014769A1/en not_active Abandoned
- 2002-10-10 PL PL02369822A patent/PL369822A1/xx unknown
- 2002-10-10 EP EP02802624A patent/EP1441721A2/fr not_active Withdrawn
- 2002-11-08 AR ARP020104289A patent/AR037343A1/es not_active Application Discontinuation
-
2004
- 2004-06-08 ZA ZA200404544A patent/ZA200404544B/en unknown
Non-Patent Citations (1)
Title |
---|
See references of WO03039539A2 * |
Also Published As
Publication number | Publication date |
---|---|
HUP0402281A2 (hu) | 2005-02-28 |
WO2003039539A3 (fr) | 2003-11-06 |
JP2005510511A (ja) | 2005-04-21 |
KR20050035181A (ko) | 2005-04-15 |
DE10155076A1 (de) | 2003-05-22 |
BR0213684A (pt) | 2004-10-26 |
WO2003039539A2 (fr) | 2003-05-15 |
ZA200404544B (en) | 2005-02-08 |
AR037343A1 (es) | 2004-11-03 |
RU2004117596A (ru) | 2005-05-27 |
PL369822A1 (en) | 2005-05-02 |
MXPA04004306A (es) | 2004-08-11 |
CN1585636A (zh) | 2005-02-23 |
US20050014769A1 (en) | 2005-01-20 |
CA2465744A1 (fr) | 2003-05-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2003039539A2 (fr) | Utilisation d'antagonistes du recepteur de l'endotheline dans le traitement de maladies tumorales | |
DE60305193T2 (de) | Neue 2-amino-4-oxochinazolone als partielle lxr-kernrezeptoragonisten | |
DE60031127T2 (de) | Nsaid und egfr kinase inhibitoren enthaltende pharmazeutische formulierung zur behandlung oder inhibierung von dickdarmpolypen und kolorektalem krebs | |
US11542257B2 (en) | Arylnaphthalene compounds as vacuolar-ATPase inhibitors and the use thereof | |
DE60200492T2 (de) | Kombination eines Inhibitoren der Serotoninwiederaufnahme und eines atypischen Antipsychotikums zur Behandlung von Depression, Zwangsneurosen und Psychosen | |
US20110098267A1 (en) | Topical formulations for the treatment of psoriasis | |
DE60210760T2 (de) | Verwendung von nk-1-rezeptorantagonisten gegen benigne prostatahyperplasie | |
EP2861573B1 (fr) | Dérivés de l'oxathiazine comme agents antibacteriens et anticancéreux | |
CN110785170B (zh) | 脂肪细胞的治疗 | |
DE60006099T2 (de) | Chinolinderivate als mek enzym-inhibitoren | |
KR20080031440A (ko) | Gsk-3 저해제 | |
CN102245174B (zh) | 鞘氨醇-1-磷酸受体拮抗剂与抗微管剂之间的协同作用 | |
KR20070064414A (ko) | 세포 증식 제어를 위한 chk1 억제제의 용도 | |
US9040573B2 (en) | Anti-fungal agent | |
DE60223031T2 (de) | Arylpiperazin gebundene tetrahydroindolonderivate | |
EP0303951B1 (fr) | Dérivés de 2-pyrimidinyl-1-pipérazine pour le traitement de l'alcoolisme | |
WO2003032993A1 (fr) | Utilisation d'inhibiteurs de la phosphodiesterase iv | |
JP2001511763A (ja) | 尿失禁の治療のための5−ht▲下1a▼受容体アンタゴニストの使用 | |
DE60112966T2 (de) | Trizyklische indolderivate mit antiangiogenischer wirkung | |
WO2017142269A1 (fr) | Nouveau dérivé indole et composition anticancéreuse contenant ce dernier | |
US11884653B2 (en) | Arylnaphthalene compounds as vacuolar-ATPase inhibitors and the use thereof | |
JP2021532144A (ja) | ロダニン誘導体を有効成分として含む骨関節炎の予防、改善または治療用薬学的組成物 | |
DE60308390T2 (de) | Behandlung von Hyperurikämie | |
EP3755334A1 (fr) | Traitement de maladies hépatiques | |
TWI403509B (zh) | 一種用以治療癌症之藥學組合物 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
17P | Request for examination filed |
Effective date: 20040316 |
|
AK | Designated contracting states |
Kind code of ref document: A2 Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR IE IT LI LU MC NL PT SE SK TR |
|
AX | Request for extension of the european patent |
Extension state: AL LT LV MK RO SI |
|
RIN1 | Information on inventor provided before grant (corrected) |
Inventor name: GRELL, MATTHIAS Inventor name: AMENDT, CHRISTIANE Inventor name: MEDERSKI, WERNER Inventor name: DORSCH, DIETER Inventor name: OSSWALD, MATHIAS |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN |
|
18D | Application deemed to be withdrawn |
Effective date: 20050502 |